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Prostaglandin (PG) E2 is a potent hyperthermic agent and has been assigned an intermediary
function in the response ofthermoregulatory neurons topyrogens. Though attractive, this idea has
been challenged on several grounds. The present study confirms that brain PGE2 synthesis
increases during fever, the time course of the elevation according with a causative role of the
compound. Our experimental data also argue against the involvement ofa second cyclooxygenase
product, specifically thromboxane (TX) A2, in the action of pyrogens. The sequence of events
leading to PGE2 production and fever differs depending on the pyrogen, bacterial vs. leucocytic,
and its route of administration. Blood-borne interleukin-1 (IL-1) acts on a discrete site in the
central nervous system (CNS) which is tentatively identified with the organum vasculosum
laminae terminalis (OVLT). The same site may also be the target for blood-borne endotoxin. In
addition, endotoxin may promote PGE2 synthesis in the cerebral microvasculature. Both
pyrogens, on the other hand, act diffusely throughout the CNS when given intrathecally. We
conclude that PGE2 is well suited for an intermediary role in the genesis of fever and ascribe the
reported inconsistencies to methodological factors.
Considerable evidence implicates a product ofarachidonatecyclooxygenase, specifi-
cally prostaglandin (PG) E2, in the genesis of pyrogen fever [1]. According to this
proposal, PGE2 formed within the brain in response to blood-borne interleukin-1
(IL-1), and possibly endotoxin as well, acts at an appropriate place in the thermoregu-
latory pathways to move upward the "set-point" around which temperature is
regulated. Though attractive, this scheme has been challenged by several investigators
and their arguments are summarized in Table 1. Briefly, inconsistent findings fall
under three broad categories dealing with, respectively, the lackofcorrelation between
the occurrence offever and rate ofPGE2 synthesis (Table 1, a tod), the involvement of
a second cyclooxygenase product acting in concert with, or substitution of, PGE2 as a
mediator of fever (Table 1, e to g), and the uncertainty on the location of the site, or
sites, in which pyrogen action is translated into enhanced PGE2 formation
(Table 1, h).
We will focus this paper on a few issues, currently addressed in our laboratory, that
need to besettled before accepting the scheme under debate. They include thequestion
of the variability in the reported levels of PGE2 in the cerebrospinal fluid (CSF), the
feasibility of thromboxane (TX) A2 acting as a fever mediator, and the ability of
blood-borne pyrogens to promote PGE2 synthesis at the blood-brain interface and in
the substanceofthe brain. Other issues areadequately covered in the remaining papers
ofthis section.
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TABLE 1
Evidence Against a Role of PGE2 in the Mediation of Pyrogen Fever
Finding Reference
a. Reported PGE2 levels in CSF are variable and the range ofvalues under afebrile
and febrile conditions overlap [2-8]
b. Rate ofPGE2 release in the rostral hypothalamus does not correlate with the fever
following intravenous endotoxin [9]
c. Salicylate at an appropriate dose prevents PGE2 elevation in the CSF but not the
fever response to intravenous IL-1 [5]
d. Inhibition ofprotein synthesis attenuates fever to systemic pyrogens without caus-
ing a concomitant fall in PGE2 levels in the CSF [4]
e. Prostaglandin antagonists interfere with the fever to intraventricular PGE2 while
leaving pyrogen action unaffected [10]
f Animals with extensive lesions ofthe rostral hypothalamus develop fever to intra-
venous pyrogen but not to intrathecal PGE2 [9]
g. Newborns may respond to pyrogens but not PGE2 [ 11]
h. Systemic pyrogens, bacterial and leucocytic, promote PGE2 synthesis in brain de-
spite their apparent inability to cross the blood-brain barrier [12-14]
PGE2 IN CEREBROSPINAL FLUID: AFEBRILE VS. FEBRILE STATE
A precise measurement ofPGE2 levels in CSF is crucial for theunderstanding ofthe
sequence of events leading to fever. Unhappily, many published figures have been
obtained prior to the refinement of analytical methods, using a biological assay or
immunological assays in which either the antibody was unspecific or chemical
transformation of PGE2 to PGB2 was required. Not surprisingly, PGE2 values are
widely scattered and, though pointing to an elevation during fever, are not entirely
convincing.
We have re-examined this issue using conscious cats with a sampling cannula
chronically implanted inside the third ventricle and have shown that PGE2 is mostly
undetectable (<100 pg/ml) when CSF is collected in the absence offever. Our finding
is at variance with earlier data and has been discussed elsewhere [15]. At the same
time, we have found that PGE2 content of the CSF is variably altered by fever,
depending on the pyrogen used and its route ofadministration.
Bolus injection ofIL-I into the third ventricle caused fever and stimulation ofPGE2
synthesis. The latter effect was reflected in fewer samples with subthreshold activity
and sustained rise in the measured levels of the compound (about 800 pg/ml). PGE2
elevation was instead marginal during the monophasic fever following intravenous
bolus injection of IL-1.
Unlike IL-1, endotoxin could clearly promote PGE2 synthesis by either route,
though magnitude and consistency of effects were greater with the intrathecal route.
When given intravenously, endotoxin was effective in about 60 percent of the
experiments, and its action persisted throughoutthefever. The reason for thefailures is
not clear; however, the position of the sampling cannula may be important since
highest PGE2 values (maximum, 1.1 ng/ml) were obtained with the cannula located
closer to the anterior recess of the third ventricle. Intracerebroventricular endotoxin,
on the other hand, mimicked IL-I in causing a sustained PGE2 elevation in all cases.
Significantly, this elevation preceded the onset ofthe fever.
The discrete change in PGE2 following an intravenous bolus of IL-1 cannot be
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ascribed to the short half-life of the pyrogen in the circulation, and the attendant
transient action on the central nervous system (CNS), because similar results were
obtained in experiments in which IL-1 was administered by continuous intravenous
infusion and the resulting fever was sustained. On the other hand, brain tissue has
little, if any, prostaglandin catabolic activity [16] and no significant breakdown of
PGE2 is expected under any condition. Indeed, separate experiments proved that
15-keto-13, 14-dihydro PGE2 is not detectable (<140 pg/ml) in CSF collected both in
the absence and the presence offever.
We conclude that endotoxin is a better stimulus than IL-1 in eliciting PGE2
synthesis by the intravenous route, suggesting a more direct, or diffuse, action for that
pyrogen on the CNS. Both pyrogens promote PGE2 synthesis by the intrathecal route
and, consistent with a mediator role for this prostaglandin, the effect is already
detected during the latent period ofthe fever. Overall, our values for PGE2 content of
the CSF are lower than those reported in early studies, and this finding introduces an
element ofdoubt in certain data (Table 1, cand d) purportedlycontradicting the PGE2
mediator idea. In fact, contrary to the evidence presented in Table 1, recent work
employing a specific radioimmunoassay procedure has shown that pyrogen fever and
PGE2 elevation abate in parallel after administration of a protein synthesis inhibitor
[17].
THROMBOXANE A2 AND FEVER
Under certain conditions, pyrogens remain effective despite the apparent lack of a
functional PGE2 mechanism (Table 1, e to g) and the resulting fever is susceptible to
antipyretic treatment. This observation would imply that a second cyclooxygenase
product acts as a fever mediator and, mainly by exclusion, TXA2 has been considered a
suitable candidate. In support ofthis view are the occurrence ofactive TXA2 synthesis
in the brain parenchyma [16] and the notion that stable endoperoxide analogs, which
are known to behave as TXA2 mimics in other systems, may alter body temperature
[18,19].
We have examined this possibility and initial results, particularly the demonstration
ofan antipyretic action for imidazole, were promising [15]. However, our recent work
does not provide support for this idea and specific findings are summarized below.
1. A stable TXA2 analog, 9,1 1-epithio-11,12-methano-TXA2 (ONO-I I 1 13, 2,4g
IVT), produced variable changes in body temperature (hyper- or hypothermia) or no
effect at all.
2. Fever to intracerebroventricular endotoxin was not modified by treatment with
the thromboxane antagonist, 9,1 1-dimethylmethano-11,12-methano-16-phenyl-13,14-
dihydro-13-aza-15af#-w-tetranor-TXA2 (ONO-l 1 120). The compound (2 ,ug IVT)
was given five or 35 minutes after endotoxin with identical results.
In addition, we found that intravenous pyrogen, both bacterial and leucocytic, is
consistently without effect on TXB21 levels in the CSF. Intracerebroventricular
pyrogen, on the other hand, promoted thromboxane synthesis, but stimulation was
limited to an early stage of the fever response. Both results differ from those obtained
with PGE2.
While arguing against the involvement of TXA2, the above findings leave open the
question ofan alternative fever mediator being formed in thecyclooxygenase pathway.
'TXB2 is the stable byproduct ofTXA2 and its measurement provides an indexofthe rate ofthromboxane
synthesis.
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At thesame time, however, they call for a closerscrutinyoftheevidencesupporting the
existence of such mediator. For example, PGE2 antagonists are poorly soluble in
aqueous media and, when injected intraventricularly, may affect differently responses
to the exogenous and endogenous prostaglandin. Likewise, the apparent lack of effect
ofintraventricular PGE2 in animals with extensive lesions ofthe rostral hypothalamus
could simply reflect impaired diffusion of the compound to the target site. Unfortu-
nately, no information is available on the ability of these animals to develop fever in
response to systemic PGE2. Lastly, analysis of results in the newborn must take into
account the existence of an endogenous antipyretic principle, possibly identified with
arginine vasopressin [20]. Such an agent may interact in a variable manner with
pyrogens and PGE2 during the early neonatal period. All these questions need to be
answered before again approaching the problem ofa second fever mediator.
SITE OF PYROGEN ACTION IN THE CNS
Blood-borne IL-1 is conventionally regarded as the common intermediary for a
multiplicity offever-producing agents and conditions. Nevertheless, its mode ofaction
on the CNS is unclear because, on the one hand, the blood-brain barrier is seemingly
impermeable to pyrogens [12-14] and, on theother hand, intrathecal administration of
a cyclooxygenase inhibitor results in suppression of fever [21]. The latter finding
implies that pyrogen action is exerted within the brain parenchyma or, perhaps, in the
microvasculature. Alternatively, the pyrogen could act outside the blood-brain barrier
in a circumventricular organ. One such organ, the organum vasculosum laminae
terminalis (OVLT), is connected with the median pre-optic area and is ascribed a role
in the genesis of fever [22]. In fact, our data suggest that IL-I action is confined to a
discrete brain region.
To gather more information on the location of IL-I-responsive site(s), we have
studied the effect ofintravenously infused IL-I in cats pretreated with probenecid (30
mg/kg IP or IV; 50 or 100 gtg IVT). Probenecid interferes with the transport of
prostaglandins from brain to blood [23] and, therefore, would seem a suitable tool for
"magnifying" any PGE2-linked effect of IL-1. However, findings did not differ from
those obtained in naive animals, and PGE2 elevation remained marginal throughout
the fever.
A more direct approach to this problem was taken in subsequent experiments in
which PGE2 release was monitored in vitro and in vivo using, respectively, isolated
cerebral microvessels and "push-pull" perfusion cannulas positioned inside the rostral
hypothalamus.
Cerebral Microvessels
The idea ofthe intraparenchymal microvasculature being the target for blood-borne
pyrogens is conceptually appealing and also accords with some experimental observa-
tions. The hypothalamus is richly vascularized and blood vessels are endowed with an
active prostaglandin-generating system [24]. Furthermore, hypothalamic blood flow is
increased during fever [25], possibly reflecting stimulation of prostaglandin synthesis
in the vessel wall.
Cerebral microvessels, consisting mostly ofcapillaries, released PGE2 in the amount
of about 70 pg/mg protein/minute and this release rate doubled during exposure to
endotoxin (10 ,ug/ml). IL-I (maximum, one rabbit pyrogenic dose/ml) had instead an
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FIG. 1. Hypothesis on the mecha-
nism by which pyrogens, bacterial and
leucocytic (IL-1), promote PGE2 syn-
thesis in the central nervous system,
thus causing fever. A different se-
quenceofevents is envisageddepending
onwhetherthepyrogen isgiven system-
ically or intrathecally. Note that brain
may produce IL-I (shown within inter-
rupted lines) upon direct endotoxin
challenge. OVLT, organum vasculo-
sum laminae terminalis.
toryaction ofendotoxin, ifrepresentative ofthecondition in vivo, could account for the
observed rise in PGE2 content ofthe CSF.
LocalPerfusion ofthe Hypothalamus
PGE2 release was monitored at discrete hypothalamic sites, using a modified
"push-pull" perfusion procedure in which stringent precautions were taken to avoid
damage to the tissue. In the absence of fever, the release rate was generally below
detection (<0.5 pg/minute), but rose to measurable levels in most experiments in
which probenecid was added to the perfusion fluid (final concentration, 1 mM). Even
during local probenecid treatment, however, intravenous IL-1 caused only a slight
increase in the concentration of PGE2 in the effluent. Unfortunately, sites studied so
far were located mostly in the anterior hypothalamus and inadequate screening ofthe
pre-optic area could account for this modest response.
CONCLUSION
The arguments listed in Table 1 form collectively a convincing case against the
existence of a "PGE2 link" in the central action of pyrogens. Their significance,
however, is greatly weakened by methodological problems and incomplete experimen-
tal verification. Equally debatable is the occurrence of a second cyclooxygenase
product with pyrogenic properties. In our view, PGE2 remains the best candidate for
mediating the response of thermoregulatory neurons to pyrogens, and a tentative
scheme integrating our data as well as data of others is given in Fig.1. Systemic
endotoxin may promote PGE2 synthesis in brain capillaries. It may also be possible for
endotoxin, or rather an active fragment derived from its breakdown, to cross the
choroidal barrier in small amounts. The action of this pyrogenic moiety would be
"amplified" within the confines of brain since our current work indicates the
appearance of IL-I in CSF of cats treated with intracerebroventricular endotoxin
[Coceani F, Dinarello C, Lees J: unpublished]. Both endotoxin and IL-I gain access to
neurons in the OVLT and may initiate a sequence of events leading to the local
formation ofPGE2 in the rostral hypothalamus. Intraventricularly injected pyrogens,
on the other hand, act diffusely throughout the brain.
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